<DOC>
	<DOCNO>NCT02056743</DOCNO>
	<brief_summary>The purpose study evaluate possibility drug interaction take red ginseng fermented-red ginseng estimate metabolic rate indicator drug cytochrome P450 P-glycoprotein .</brief_summary>
	<brief_title>Clinical Trials Evaluate Red Ginseng Fermented-Red Ginseng Affect Drug Metabolizing Enzyme Transporter Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Caffeine</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<mesh_term>Dextromethorphan</mesh_term>
	<mesh_term>Fexofenadine</mesh_term>
	<mesh_term>Terfenadine</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>Healthy male subject age 20 55 year . Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight &gt; 45 kg . An informed consent document sign date subject . Subject willing able comply schedule visit , treatment plan , laboratory test , study procedure . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) Any condition possibly affect drug absorption ( e.g . gastrectomy ) History regular alcohol consumption exceed 21 drinks/week ( 1 drink = 150 mL wine 360 mL beer 45 mL hard liquor ) within 6 month Screening Participating bioequivalence study clinical study within 3 month precede first dose study medication Screening sit blood pressure &gt; 160 mm Hg ( systolic ) &gt; 90 mm Hg ( diastolic ) , follow least 5 minute rest . History significant alcohol abuse drug abuse within one year prior Screening Use drug know significantly induce inhibit drugmetabolizing enzyme within 30 day prior dose Smoking 20 cigarette per day Use prescription nonprescription drug dietary supplement within 10 day 5 halflives ( whichever longer ) prior first dose study medication . Blood donation within 2 month prior dose , plasma donation within 2 week prior dose Unwilling unable comply Lifestyle guideline describe protocol Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation investigational product administration may interfere interpretation study result , judgment investigator , would make subject inappropriate entry study Subjects hypersensitive investigational drug related compound Subjects hereditary disease galactose intolerance , Lapp lactase deficiency gulucosegalactose malabsorption Subjects decide incongruity participate study investigator</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>